Vancouver, Canada

Time filter

Source Type

Title: Prospective study of biopsy Decipher scores in potential candidates for active surveillance Date: Saturday, May 13 (2:40 p.m. to 2:50 p.m. EST) Presentation Number: PD28-11 Room: BCEC - Room 205BC Presenter: Stacy Loeb, M.D., MSc, New York University Title: The Diverse Genomic Landscape of Low-risk Prostate Cancer Date: Monday, May 15 (10:15 a.m. to 10:20 a.m. EST) Presentation Number: PNFBA-09 Room: BCEC - Ballroom East Presenter: Matthew Cooperberg, M.D., M.P.H., University of California, San Francisco Title: Decipher Test Impacts Decision-Making among Patients Considering Adjuvant and Salvage Treatment following Radical Prostatectomy: Interim Results from the Multicenter Prospective PRO-IMPACT Study Date: Tuesday, May 16 (9:30 a.m. to 9:40 a.m. EST) Presentation Number: PD71-01 Room: BCEC - Room 162 Presenter: John L. Gore, M.D., M.S., University of Washington School of Medicine Title: Genomic Classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation in patients with prostate cancer: Development and internal validation of a multivariable prognostic model Date: Tuesday, May 16 (9:40 a.m. to 9:50 a.m. EST) Presentation Number: PD72-02 Room: BCEC - Room 205BC Presenter: Deepansh Dalela M.D., Henry Ford Health System Title: Molecular subtypes of muscle invasive bladder cancer are related to benefit from neoadjuvant chemotherapy: Development of a single sample patient assay Date: Saturday, May 13 (9:30 a.m. to 11:30 a.m. EST) Presentation Number: MP34-01 Room: BCEC - Room 253AB Presenter: Roland Seiler, M.D., University of British Columbia - Vancouver Title: Development and validation of novel genomic classifiers for prediction of adverse pathology after prostatectomy Date: Sunday, May 14 (1:00 p.m. to 3:00 p.m. EST) Presentation Number: MP57-18 Room: BCEC - Room 153 Presenter: Firas Abdollah, M.D., Henry Ford Health System Title: Assessing Decipher for predicting lymph node positive disease among men diagnosed with intermediate risk disease treated with prostatectomy and ePLND Date: Sunday, May 14 (3:30 p.m. to 5:30 p.m. EST) Presentation Number: MP64-12 Room: BCEC - Room 156 Presenter: John Davis, M.D., MD Anderson Cancer Center GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment. Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment. More information is available at www.deciphertest.com and www.deciphergrid.com GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedxs-decipher-grid-and-decipher-tests-to-be-featured-in-multiple-abstracts-at-the-112th-american-urological-association-annual-meeting-300451255.html


The study, "Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease," was published online ahead of print in Journal of Clinical Oncology. The study performed the first meta-analysis of the performance of Decipher Post-Op in men following RP and included a total of 855 patients across five studies.  Results showed that Decipher further improved prediction of metastasis (AUC 0.81) at 10 years after prostate surgery versus the clinical model alone. Further demonstrating the clinical validity of Decipher Post-Op, the study, "Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model," was also published online ahead of print in Journal of Clinical Oncology. The purpose of the study was to develop a risk stratification tool incorporating the Decipher score, along with routinely available clinicopathologic features to identify which patients would benefit the most from adjuvant radiation therapy (ART).  The cohort included 512 prostate cancer patients treated with RP at multiple institutions between 1990-2010.  Results showed that incorporating Decipher added prognostic value in identifying patients with adverse pathologic features, which might reduce overtreatment, decrease unnecessary adverse effects, and reduce risk of clinical recurrence in the subset of prostate cancer patients who benefit from ART. The clinical validity of Decipher Post-Op was also featured in the study, "Validation of a Genomic Risk Classifier to Predict Prostate Cancer Specific Mortality in Men with Adverse Pathologic Features," published online ahead of print in European Urology. The multi-institutional study included 561 men at intermediate and high risk for prostate cancer progression that underwent RP between 1987-2010, and demonstrated the ability Decipher Post-Op to predict likelihood of prostate cancer specific mortality in patients ten years after their prostate surgery, independent of standard risk models. GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment. Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment. More information is available at www.deciphertest.com and www.deciphergrid.com GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/multiple-studies-further-validate-the-importance-of-decipher-post-op-in-the-treatment-of-prostate-cancer-300469975.html


A system for expression-based discrimination of distinct clinical disease states in prostate cancer is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated with recurrent or non-recurrent prostate cancer. The Prostate Cancer Prognostic system provides for sets of prostate cancer prognostic target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying prostate cancer tissue.


Patent
GenomeDx Biosciences | Date: 2015-10-29

A system for classifying thyroid nodule tissue as malignant or benign is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated to with either malignant or benign thyroid nodule disease. The thyroid classification system provides for sets of thyroid classifying target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying thyroid nodule tissue.


Patent
GenomeDx Biosciences | Date: 2013-09-06

Disclosed herein, in certain instances, are methods for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods for determining the treatment modality of a cancer in a subject. The methods comprise expression-based analysis of targets. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject.


Patent
GenomeDx Biosciences | Date: 2015-06-01

A system for classifying thyroid nodule tissue as malignant or benign is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated to with either malignant or benign thyroid nodule disease. The thyroid classification system provides for sets of thyroid classifying target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying thyroid nodule tissue.


Patent
GenomeDx Biosciences | Date: 2014-03-11

Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject. Further disclosed herein are classifiers for analyzing a cancer.


Patent
Mayo Foundation For Medical Education And Research and GenomeDx Biosciences | Date: 2013-08-16

Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject.


Patent
GenomeDx Biosciences | Date: 2012-12-13

Disclosed herein, in certain instances, are methods for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods for determining the treatment modality of a cancer in a subject. The methods comprise expression-based analysis of non-coding targets and coding targets. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject.


Patent
University of British Columbia and GenomeDx Biosciences | Date: 2014-11-04

The present invention relates to methods, systems and kits for the diagnosis, prognosis and the determination of cancer progression of cancer in a subject. The invention also provides methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, certain instances, are probe sets for use in assessing a cancer status in a subject. Further disclosed herein are classifiers for analyzing a cancer, such as, for example, bladder cancer.

Loading GenomeDx Biosciences collaborators
Loading GenomeDx Biosciences collaborators